is well established as a growth-inhibitory, apoptosis-inducing secreted molecule that acts via insulin-like growth factor (IGF)-independent as well as IGF-dependent pathways. Nuclear localization of IGFBP-3 has been observed and nuclear binding partners for IGFBP-3 demonstrated. However, little is known about the mechanism of IGFBP-3 internalization. We hypothesized that IGFBP-3 is first secreted then taken up again into cells and that its internalization could occur via binding to transferrin or caveolin. Incubation of cells with an IGFBP-3-neutralizing antibody demonstrated that nuclear translocation of endogenous IGFBP-3 requires IGFBP-3 secretion and re-uptake. Nuclear localization of exogenously added IGFBP-3 was rapid, occurring within 15 min, inhibited by co-incubation and extracellular sequestration with IGF-I, and dependent on the transferrin-binding C-terminal peptide region of IGFBP-3. Co-immunoprecipitation assays confirmed that IGFBP-3 binds transferrin but not directly to the transferrin receptor (TfR1); however, transferrin binds TfR1 and a ternary complex is formed. Specific binding to caveolin scaffolding docking sequence was confirmed utilizing radiolabeled IGFBP-3. Blocking TfR1-mediated endocytosis prevents both endogenous and exogenous IGFBP-3 re-uptake and inhibitors of caveolae formation also retard IGFBP-3 nuclear entry. Co-treatment with anti-transferrin receptor antibody and cholesterol depletion agents completely abolished endogenous and exogenous IGFBP-3 uptake. Suppression of IGFBP-3 internalization by TfR1 blockade inhibited IGFBP-3-induced apoptosis. Together, these data indicate that the actions of IGFBP-3 are mediated by internalization via distinct endocytic pathways.
Substantial progress over the past decade has validated the insulin-like growth factor binding proteins (IGFBPs) 1 as unique intrinsic effectors of cellular growth and apoptosis, properties that can be unrelated to their ability to bind IGFs (for review see Ref. 1) . Several lines of evidence support insulin-like growth factor binding protein-3 (IGFBP-3) as a biological mediator of cancer cell apoptosis (2) . Previously, we have described IGFBP-3 as the mediator of both TGF-␤-and TNF-␣-induced apoptosis using antisense oligonucleotides or neutralizing antibodies to IGFBP-3 in PC-3 prostate cancer cells (3, 4) . Nuclear localization of IGFBP-3 is a well described phenomenon and has been demonstrated in a variety of cellular models (5) (6) (7) (8) . IGFBP-3 possesses a consensus bipartite nuclear localization sequence (9) , and nuclear transport is facilitated by importin-␤ factor (10) .
Although advances have been made in our understanding of these IGF-independent effects, including novel nuclear effects on retinoid X receptor-mediated signaling (8) , the mechanisms and pathways by which IGFBP-3 is internalized into the cell are poorly understood. The long-standing search for IGFBP-cell surface receptors has not yet provided definitive results.
It is unclear at this time whether IGFBP-3 can act as an intracrine molecule or whether it needs to be secreted and re-uptaken (in an autocrine/paracrine fashion) back into cells. Furthermore, it is unknown how IGFBP-3 enters the cells. Current understanding of macromolecular entry into cells includes two major endocytic pathways, caveolin-and clathrinmediated uptake.
IGFBP-3 binding to transferrin has been shown by us (11) to be dependent on a region in the C-terminal domain shown in Fig. 1 . Analysis of the IGFBP-3 amino acid sequence also demonstrated that a caveolin-scaffolding domain consensus sequence (CSD, ØXØXXXXØ, where Ø is a hydrophobic residue and X is any amino acid residue) (12) , FCWCVDKY, also resides near the C-terminal end of IGFBP-3 ( Fig. 1 ). This offered caveolin-1 as an attractive membrane protein partner for IGFBP-3 as well as a mediator of IGFBP-3 internalization.
To resolve some of the issues related to the process of IGFBP-3 internalization, we examined the effect of membrane cholesterol depletion (as a method of blocking caveolin-dependent uptake) and blockade of the transferrin receptor (to ar-rest clathrin-mediated uptake) on the nuclear localization of IGFBP-3 in prostate cancer cells. Our data demonstrate the requirement for IGFBP-3 secretion and re-uptake for efficient apoptosis. IGFBP-3 binds transferrin, which then binds the transferrin receptor for subsequent internalization. The specific disruption of caveolae organization also inhibited IGFBP-3 endocytosis, whereas blockade of both transferrin receptor and caveolin-mediated pathways completely impedes IGFBP-3 internalization. These data are consistent with a model wherein caveolae and clathrin-mediated (specifically transferrin/TfR1) endocytosis function together to mediate the efficient endocytosis of IGFBP-3.
EXPERIMENTAL PROCEDURES
Materials-Recombinant human IGFBP-3 and NLS mutant K228E, R230G were generously provided by Dr. Despond Mascarhenas of Protigen Inc. (Mountain View, CA). The IGFBP-3 polyclonal antibody and 125 I-rhIGFBP-3 were purchased from DSL (Webster, TX). Human recombinant IGF-I, and analogues (LR 3 and Leu-60) were from Gropep (Australia). DAPI, PARP antibody, Hsp60 antibody, rhodamine/Texas Red-labeled IgG, methyl-␤-cyclodextrin, nystatin, progesterone, TNF-␣, and CelLytic TM NuCLEAR TM nuclear fractionation kit were from Sigma. Recombinant human TGF-␤1 was from R&D Systems (Minneapolis, MN). Human transferrin and G418 was purchased from Invitrogen. Transferrin antibody was purchased from Chemicon (Temecula, CA). Transferrin receptor-1 antibody was from Research Diagnostics (Flanders, NJ). SDS-PAGE reagents, Tween, and fat-free milk were purchased from Bio-Rad. The caveolin scaffolding docking peptide (DGIWKASFTTFTVTKYWFYR) and non-binding peptide (NRDP-KHLNDDVVKIDFEDVIAEPEGTHSF) were synthesized and purchased from Genemed (South San Francisco, CA). A caspase-3/-7 specific fluorometric assay (ApoONE TM , Promega, Madison, WI) was used as a measure of apoptosis induction.
Co-immunoprecipitation and Western Immunoblots-Chinese hamster ovary (CHO) cells, which normally do not express the TfR1, have been stably transfected to overexpress the TfR1 (13) . Whole cell lysates were pre-precipitated (if indicated) with anti-transferrin antibodies. Briefly, 250 l of protein A-agarose was incubated overnight at 4°C with 5 l of anti-human transferrin antibodies. 125 l of each antibodytreated protein A-agarose was added to 10 g of CHO-TfR1 cell lysates and incubated for 3 h at 4°C with shaking. Immunoprecipitated proteins were pelleted by centrifugation. This immunodepleted (if indicated) supernatant was subjected to protein A-agarose bound to described antibody as above, precipitated, and washed 3 times with 100 l of SACI buffer. 200 l of sample buffer was added to each sample and vortexed vigorously. Samples were boiled and vortexed again to release protein-antibody complexes from the protein A-agarose. The protein A-agarose was then separated from the immunoprecipitated complexes by centrifugation. The supernatants were saved, and the cycle was repeated if indicated with another antibody, and the immunoprecipitated proteins were separated by nonreducing SDS-PAGE (8%) at constant voltage overnight and then transferred to nitrocellulose for 4 h at 170 mA. The nitrocellulose was immersed in blocking solution (5% non-fat milk/TBS) for 45 min, washed with TBS, 0.1% Tween, and incubated with primary anti-human TfR1 or anti-human IGFBP-3 antibody (1:4000) for 2 h. After washing off any unbound antibodies, the nitrocellulose was incubated with a secondary antibody (1:10,000) for 1 h. The membrane was washed 4 times with TBS, 0.1% Tween, and TBS. Bands were visualized using the peroxidase-linked enhanced chemiluminescence detection system (ECL, Amersham Biosciences). Experiments were repeated 3 times.
Ligand Dot Blot-Western ligand blots were used to assess IGFBP-3 binding. Peptides (2 l at a time) were carefully dot-blotted directly onto PVDF membrane (membrane presoaked in methanol and subsequently balanced in PBS) and allowed to dry completely. PVDF membrane was then wet again with methanol, soaked in distilled H 2 O, and then buffered in Tris-buffered saline (TBS) Ϫ3% Igepal CA-630 with gentle shaking for 30 min at 4°C, after which the membrane was blocked with TBS, 1% bovine serum albumin for 3 h at 4°C. Tissue Culture-LAPC-4 cells were a kind gift from C. Sawyers (UCLA, Los Angeles, CA). LAPC-4 cells (14) were cultured in Iscove's modified Dulbecco's medium containing 10% fetal bovine serum, 1% L-glutamine, 1% R1181 (PerkinElmer Life Sciences). 22 RV1 and PC-3 prostate carcinoma cell lines (ATCC, Manassas, VA) were grown according to recommended protocols. TfR1-transfected CHO Cells (13) were maintained in F12 medium (Invitrogen) supplemented with 5% fetal bovine serum and 200 g/ml G418. For each indicated experiment, cells were dissociated, centrifuged, and resuspended in serum-containing medium with antibiotics and inoculated at a density of 1 ϫ 10 5 cells/cm 2 in 24-or 6-well tissue culture dishes and grown to 60 -70% confluence in a humidified atmosphere of 5% CO 2 at 37°C before treatment. After a quick wash with serum-free media, the cells were treated with various concentrations of the specified reagents for the specific times indicated. Serum-free media with antibiotics were used as the control treatment.
Subcellular Fractionation/Nuclear Localization Assessment-Cells were pulsed or treated with the indicated reagents for the indicated times under serum-free conditions, and the CelLytic TM NuCLEAR TM Extraction kit (Sigma) was used according to the manufacturer's instructions to separate nuclear and cytoplasmic fractions from whole cell lysates. The procedure for the nuclear protein extraction method is to allow cells to swell with hypotonic buffer. The cells are then disrupted; the cytoplasmic fraction is removed, and the nuclear proteins are released from the nuclei by a high salt buffer. Equal amounts of protein were quantitated (Lowry reagent, Bio-Rad) and separated by SDS-PAGE. If indicated, conditioned media were also quantitated via densitometric analysis of Western immunoblot on subcellular fractions.
Immunofluorescence Confocal Microscopy-1 ϫ 10 4 LAPC-4/PC-3/ CHO-TfR1 cells were plated on coverglass with or without reagent for the indicated times before staining for immunofluorescence. After three washes in PBS, fixation and permeabilization of the cells were performed with 1% paraformaldehyde in PBS for 15 min at room temperature and 0.2% Triton X-100 in PBS for 15 min on ice, and cells were washed twice with PBS. IGFBP-3 protein localization was detected using the DSL hIGFBP-3 goat polyclonal antibody (which was previously purified an IGFBP-3 column), diluted 1:200, followed by fluorescein/Texas Red anti-goat antibody from Vector Laboratories (Burlingame, CA). Preincubation of antibody with recombinant BP3 resulted in loss of signal indicating specificity (data not shown). Specimens were incubated with primary antibodies in PBS for 1 h at room temperature, with secondary antibodies in PBS for 40 min at room temperature, and then incubated with Hoechst (DAPI) to stain nuclei for 2 min. Samples were analyzed using the Inverted Confocal Microscope (Leica, Inc., Germany), equipped by digital camera Himamatsu (Japan), and operated by QED-image software.
Caspase Assays-For caspase assays cells were plated at equal density (10 4 cells/ml) on 96-well plates (Costar) in medium containing 10%
FIG. 1. Transferrin and caveolin binding regions of IGFBP-3.
A, the C-terminal domain of IGFBP-3 including the nuclear localization region, the transferrin-binding region, and the caveolin scaffoldingdocking domain (ØXØXXXXØ; where Ø is an aromatic residue) (12) are outlined. The IGFBP-3 mutant (BP3m) (K228E, R230G) that has impaired transferrin binding (11) is shown. B, comparison of the corresponding regions of the six known IGFBPs. The number of consensus CSD aromatic amino acids is enumerated on the right column.
fetal bovine serum and antibiotics. Cells were cultured overnight and changed to serum-free media for the experiments. rhIGFBP-3 was used at the indicated concentrations. A caspase-3/-7-specific fluorometric assay (Apo-ONE, Promega) was used according to the manufacturer's instructions to measure the degree of apoptosis induction by IGFBP-3.
Statistical Analyses-Experiments are means of triplicates, and each experiment was performed 3 times. Data are expressed as mean Ϯ S.E. Statistical analyses were performed using an unpaired t test or by analysis of variance utilizing InStat (GraphPad, San Diego, CA). Differences were considered statistically significant when p Ͻ 0.05.
RESULTS

Nuclear Translocation of IGFBP-3 Involves IGFBP-3 Secretion and
Re-uptake-Because TGF-␤1 is a potent growth inhibitor of epithelial cells and has been shown to induce apoptosis via an IGFBP-3-dependent pathway in PC-3 cells (3), we investigated the presence of nuclear IGFBP-3 in TGF-␤1-treated cells. Consistent with our previously published findings of a 10-fold increase in the presence of IGFBP-3 mRNA and protein in conditioned media of TGF-␤-treated cells, treatment of PC-3 cells with 1 ng/ml TGF-␤1 for 48 h also resulted in a 10-fold increase in IGFBP-3 secreted into conditioned media, as well as of IGFBP-3 found in the nuclear fractions and a 5-fold increase of cytoplasmic IGFBP-3 as compared with control serum-free conditions ( Fig. 2A) . When visualized by confocal indirect immunofluorescence microscopy ( Fig. 2B) , the presence of IGFBP-3 (shown in red) is clearly increased by TGF-␤ in the 2nd panel both in the nucleus (identified by the DAPI staining in blue) and in the cytoplasm. Addition of a non-internalizable neutralizing IGFBP-3 polyclonal antibody together with TGF-␤ dramatically reduced the amount of intracellular IGFBP-3, abolished the presence of nuclear IGFBP-3 shown by confocal microscopy, and markedly reduced the presence of nuclear IGFBP-3 as shown by Western immunoblot (Fig. 2C) . Residual cytoplasmic staining of IGFBP-3 may represent newly translated IGFBP-3 in the cytoplasm before secretion. We demonstrated previously that this antibody tightly binds IGFBP-3 secreted from cells as a large molecular weight non-internalized complex (data not shown). These results demonstrate that IGFBP-3 must be secreted before re-uptake and targeting to the nucleus.
Nuclear Localization of IGFBP-3 Is Rapid, IGF-inhibitable, and C-terminal Sequence-dependent-22RV1 prostate cancer cells were pulsed with 500 ng of IGFBP-3 alone or in combination with IGF-I or IGF analogue for 15 min; nuclear fractions were isolated and resolved on SDS-PAGE and immunoblotted for IGFBP-3. Fig. 3 shows a definite, intense IGFBP-3 nuclear band at 15 min with a lesser amount in the cytoplasm. The C-terminal mutant (shown in Fig. 1 ) has greatly reduced ability (ϳ10% of wild type) to localize to the nucleus, and no cytoplasmic presence is detected. The polyclonal IGFBP-3 antibody used recognizes both mutant and wild-type IGFBP-3 with similar affinities (data not shown). Co-incubation with IGF-I resulted in a dramatic retardation of nuclear entry, consistent with an expected extracellular sequestration. Co-treatment with the IGF analogue (long R3-IGF-I) that does not bind to IGFBPs did not impair cellular entry, whereas treatment with the IGF analogue (Leu-60) that has greatly reduced affinity for the type I IGF receptor with normal binding affinity for the IGFBPs did impair cellular entry. These observed effects of IGF and IGF analogues on IGFBP-3 nuclear entry recapitulate previous effects of IGF-I and its analogues on IGFBP-3-induced apoptosis (3) . Therefore, the predominant destination of the re-uptaken free IGFBP-3 is the nucleus and is dependent on the C-terminal region that binds transferrin. Of note, the residues mutated are also involved in cell surface (15, 16) and importin-␤ binding (10).
FIG. 2. TGF-␤ induces IGFBP-3 secretion and re-uptake.
A, densitometric analysis of Western immunoblots with IGFBP-3 antibody of subcellular fractions (100 g of protein was quantitated and loaded onto each lane) of cytoplasmic, nuclear, and conditioned media, obtained after treatment of PC-3 cells for 24 h with 1 ng/ml TGF-␤. SF, serum-free. B, confocal microscopy of PC-3 cells. DAPI is a nucleus-specific stain (blue). IGFBP-3 protein was detected using hIGFBP-3 antibody followed by Texas Red-labeled IgG (red). SFM, serum-free media. C, Western immunoblot on nuclear fractions of PC-3 cells treated with TGF-␤ plus or minus an IGFBP-3-neutralizing antibody. 1 ng/ml treatment with TGF-␤ treatment for 24 h increased IGFBP-3 secretion as well as nuclear IGFBP-3. Co-incubation with an anti-IGFBP-3 antibody blocks IGFBP-3 re-uptake and translocation to the nucleus.
IGFBP-3 Binds Transferrin but Not Directly to Transferrin
Receptor-1 (TfR1); However, a Ternary Complex May be Formed-We and others (11, 17) have described transferrin as an IGFBP-3 binding partner. A series of co-immunoprecipitation experiments was employed to investigate whether IGFBP-3 interacts with the TfR1 either directly or as a complex bound to transferrin. CHO cells, which normally do not express the TfR1, have been stably transfected to overexpress the TfR1 (13). In Fig. 4A , these cells were immunoprecipitated with various antibodies bound to protein A-agarose, and subsequent nonreducing SDS-PAGE was immunoblotted with anti-IGFBP-3 and anti-TfR1 antibodies. In lane 2 of both Fig. 4 , A and B, lysates were depleted of transferrin with pre-precipitation by a transferrin antibody. Fig. 4A shows that TfR1 associates with transferrin but not IGFBP-3. In Fig. 4B , note that IGFBP-3 is co-immunoprecipitated by transferrin as well as by the transferrin receptor. However, pre-depleting the lysates with a transferrin immunoprecipitation results in a loss of most of the IGFBP-3 brought down by the TfR indicating that this interaction most likely involves a ternary complex of IGFBP-3, transferrin, and TfR1.
IGFBP-3 Binds CSD-We identified a caveolin scaffolding docking domain consensus sequence near the transferrin-binding C-terminal region of IGFBP-3 (Fig. 1A) . IGFBP-3 is the only binding protein that contains three consensus aromatic amino acids (Fig. 1B) . To verify the interaction between CSD and IGFBP-3, we used ligand dot blot experiments (Fig. 5, A  and B) . CSD peptide, caveolin-1 residues 82-101 (12), along with a peptide synthesized from an adjacent region of caveolin-1 (residues 53-81) used as a negative control, were immobilized to PVDF membrane. CSD peptide showed saturable binding to 125 I-labeled rhIGFBP-3 (0.5 Ci/100 l) (Fig. 5, A  and B) , as a 100-fold excess of cold IGFBP-3 (1 M) co-incubated with radiolabeled IGFBP-3 displaced binding effectively. IGF-I was used as a positive control for IGFBP-3 binding. Specificity of binding with respect to the other IGFBPs was not tested.
TfR1 Blockade Prevents Exogenous and Endogenous IGFBP-3 Uptake-We hypothesized that IGFBP-3 might internalize via a pathway that involves a classical clathrin-dependent endocytic pathway, of which the transferrin/transferrin receptor is the best studied (18) . To test whether blocking the TfR1 prevents IGFBP-3 uptake, we treated LAPC-4 cells with IGFBP-3 for 24 h after pretreatment with and without antiTfR1 antibody for 1 h. As shown in Fig. 6A , treatment with exogenous recombinant IGFBP-3 results in marked nuclear accumulation of IGFBP-3. Co-treatment with anti-TfR1 antibody shows exclusion of IGFBP-3 from the nucleus and also from cell extracts (data not shown).
To further validate this observation on endogenous IGFBP-3 production and re-uptake, CHO-TfR1 cells were treated with TNF-␣ alone or in combination with TfR1 antibody for 12 h. We have shown previously (4) that TNF-␣ treatment induces IGFBP-3 mRNA and protein production 5-10-fold. The anti-human IGFBP-3 Ab, purchased from DSL, also detects CHO IGFBP-3 (immunoblot and ELISA data not shown). An antibody to a related receptor (TfR2), serving as a control, did not block IGFBP-3 internalization (data not shown). Fig. 6B shows that after treatment with TNF-␣, these cells demonstrated a large amount of nuclear IGFBP-3 in serumfree conditions presumably secondary to increased re-uptake via increased amounts of TfR1. Blockade of the TfR1 with a specific antibody resulted in a marked decrease in both nuclear transferrin binding domain, BP3m) , or IGFBP-3 in combination with 100 ng/ml IGF-I or IGF-I analogues for 15 min. LR3 is an IGF analogue with greatly reduced affinity for the binding proteins. Leu-60 is an IGF analogue with greatly reduced affinity for the type I IGF receptor but normal affinity for the binding proteins. PARP is used as a loading control for nuclear fractions; Hsp60 is used as a loading control for cytoplasmic (Cytopl.) fractions. The graphs represent densitometric analysis of the immunoblots measured in arbitrary densitometry units (IGFBP-3/loading control) expressed as fold change versus wild-type IGFBP-3. IGFBP-3 localizes predominantly to the nucleus and can be sequestered extracellularly by IGF-I.
and total intracellular IGFBP-3 as shown by confocal microscopy. Thus, the transferrin internalization pathway participates in the internalization of IGFBP-3.
Inhibition of Caveolae Formation Also Inhibits IGFBP-3 Nuclear Entry-Although caveolae have been described recently (19) as an internalization pathway for several pathogens, including non-enveloped viruses with a classical NLS (e.g. SV40), their role as an internalization pathway for IGFBPs has not been addressed. To examine the role of this pathway, cells were treated with caveolae-inhibiting drugs. Nystatin and methyl-␤-cyclodextrin are sterol-binding drugs that sequester cholesterol and are not believed to affect clathrin-mediated endocytosis (20, 21) . As shown in Fig. 7A, 22RV1 prostate cancer cells were treated with 25 ng/ml nystatin or 10 nM M␤CD for 2 h in serum-free conditions and then pulsed with 500 ng of IGFBP-3 for 5, 10, and 15 min. Nuclear fractions were run on SDS-PAGE and immunoblotted with anti-IGFBP-3 antibody. Pretreatment with these classical cholesterol depletion agents significantly impaired IGFBP-3 nuclear entry. Nystatin inhibited nuclear entry of IGFBP-3 by over 50% at 5 and 10 min, and cyclodextrin impaired IGFBP-3 nuclear entry by Ͼ50% at 5, 10, and 15 min. Quantitation of three separate experiments done in triplicate show a Ͼ40% reduction by nystatin in nuclear IGFBP-3 transport associated with a Ͼ50% reduction in cytoplasmic IGFBP-3 (Fig. 7B) . As a positive control, treatment with nystatin and cyclodextrin also impaired nuclear and cytoplasmic transport of cholera toxin, known to internalize via caveolar pathways (22) . Thus, caveolae disruption by cholesterol depletion agents significantly impairs IGFBP-3 cellular internalization, suggesting that caveolae-mediated endocytosis also participates in IGFBP-3 internalization. Interestingly, this inhibition was lessened at 15 min, suggesting that caveolin blockade is compensated for by entry via an alternate pathway.
Disruption of Caveolin-and Transferrin-mediated Endocytosis in Combination Blocks Endogenous and Exogenous IGFBP-3 Nuclear
Entry-Our present data suggest that IGFBP-3 internalization is mediated by both classical TfR/clathrin-and caveolin-mediated pathways. Fig. 8 illustrates blockade of both pathways on both endogenous and exogenous IGFBP-3 internalization. 22RV1 cells were treated in serum-free conditions with M␤CD or TfR1 Ab alone or in combination for 1 h and then pulsed with 500 ng IGFBP-3. Nuclear fractions were isolated and resolved by SDS-PAGE under reducing conditions and immunoblotted with anti-IGFBP-3. There is a clear dose-dependent decrease in both endogenous and exogenous IGFBP-3 internalization with M␤CD. There is also a decrease in internalization as effected by the TfR1-blocking antibody. However, treatment with a combination of both agents completely abolishes endogenous IGFBP-3 re-uptake, as well as significantly diminishing exogenous IGFBP-3 re-uptake, indicating a contribution from both caveolin-and TfR/clathrin-dependent pathways in the process of IGFBP-3 internalization.
Transferrin Receptor Blockade Inhibits IGFBP-3-induced Apoptosis-As a measure of internalization blockade on IGFBP-3 function, we investigated the effect of TfR1 blockade on IGFBP-3-induced apoptosis in 22RV1 prostate cancer cells. Fig. 9 shows that as expected, IGFBP-3 induced significant rapid apoptosis as measured by fluorometric evaluation of caspase-3/-7 activity in 3 h. Pretreatment with the anti-TfR1 antibody for 2 h reduced apoptosis significantly compared with IGFBP-3 treatment alone (p Ͻ 0.005), suggesting that inhibition of IGFBP-3-transferrin-TfR1 association and subsequent internalization blockade inhibits the biological activity of this molecule, and internalization is required for the apoptotic effect of IGFBP-3 in this system. Control treatment with the antibody alone had no effect.
DISCUSSION
The interaction of IGFBP-3 with cells independently of IGFs has been studied from a number of angles. First, it is well recognized that IGFBP-3 interacts with multiple matrix proteins including heparin, proteoglycans, and collagen. IGFBP-3 has also been proposed to bind a cell surface receptor (23), but it is unlikely that this interaction facilitates internalization. The recognition of an NLS in IGFBP-3 led to further study of its 9 . Blockade of the TfR internalization pathway blocks IGFBP-3-induced apoptosis. 22RV1 cells were preincubated with anti-TfR1 Ab for 2 h and then treated with 2 g/ml IGFBP-3 for 3 h. Caspase-3/-7 activity was directly measured fluorometrically by Apo-ONE TM kit. IGFBP-3 induced apoptosis, but this effect is completely blocked by the co-incubation with anti-TfR1 antibody. Neither anti-TfR nor the combination of IGFBP-3 and anti-TfR was different from control. The combination was different from IGFBP-3 alone. *, p Ͻ 0.05 for IGFBP-3 relative to serum-free (SF). **, p Ͻ 0.005 for IGFBP-3 ϩ anti-TfR antibody compared with IGFBP-3 alone.
FIG. 7. Caveolae inhibiting agents inhibit IGFBP-3 nuclear entry.
A, 22RV1 cells were treated with 25 ng/ml nystatin or 10 nM ␤-cyclodextrin in serum-free (SF) conditions for 1 h and then pulsed with 500 ng of IGFBP-3 for 5, 10, and 15 min. Nuclear fractions were isolated using NuCLEAR TM cell fractionation kit, and 20 g of total protein was loaded into each lane. These fractions were run on SDS-PAGE and immunoblotted with anti-IGFBP-3 antibody. B, densitometric quantitation of three separate experiments performed in triplicate showing inhibition of IGFBP-3 nuclear uptake by nystatin. C, control experiment showing impairment of cholera toxin (CTX) nuclear and cytoplasmic entry when treated with nystatin (N) and ␤-cyclodextrin (CD) in combination. nuclear roles; however, the NLS does not explain the mechanism by which IGFBP-3 enters cells. Here we explore two mechanisms that facilitate the rapid internalization of IGFBP-3.
The precursor forms of all six IGFBPs have secretory signal peptides of between 20 and 30 amino acids, and the mature proteins are all found extracellularly (1) . The possibility that IGFBP-3 might re-enter the cell via the TfR1 was raised after we described its binding to serum transferrin (11) , and others described transferrin binding to IGF⅐IGFBP-3 complexes (17). Our current model involves IGFBP-3 binding to transferrin, and this binary complex binds the TfR1 with subsequent internalization of the ternary complex. Transferrin is involved in cell viability (24) , reported to regulate apoptosis negatively (25) , and blockade of the transferrin receptor prolongs pancreatic islet graft survival in vivo (26) . These observations are especially intriguing given the pro-apoptotic effects of IGFBP-3 (3, 27, 28) . TfR1 may act to promote growth in conjunction with transferrin and the absence of IGFBP-3. Alternatively, it could participate in growth inhibition and apoptosis when IGFBP-3 is present.
''Endocytosis'' encompasses distinct pathways: clathrin-mediated, caveolin-mediated, and clathrin-and caveolin-independent as well as phagocytosis and macropinocytosis. These diverse cellular corridors mediate functions such as hormonemediated signal transduction, immune surveillance, antigen presentation, and cellular and organismal homeostasis (29) . Clathrin-mediated endocytosis occurs constitutively in all mammalian cells and mediates continuous uptake of low density lipoprotein particles that bind the low density lipoprotein receptor, folate, and the extensively studied iron-laden transferrin that binds to TfR1 (30, 31) .
After formation of the early endosome, most receptors and ligands follow one of two distinct routes (32, 33) . The first one leads to late endosomes/lysosomes and is required, among other functions, for nutrient uptake and receptor down-regulation. The second one allows recycling of unloaded receptors, such as the TfR1, from the early endosome back to the plasma membrane via perinuclear recycling endosomes. This proximity to the nucleus could be a route by which IGFBP-3 obtains rapid transportation to the nucleus. A recent report (34) describes that co-incubation of transferrin with DNA in a Lipofectin-based intracellular delivery system enhanced peri-and intra-nuclear delivery of the DNA and associated transferrin co-localization.
Endocytic co-transport of both IGF-I and IGFBP-3 was originally described in 1977 (5) in opossum kidney cells. Electron microscopy confirmed localization of 125 I-IGF-I with a coated pit at the basolateral membrane and late endosomes in resting cells, consistent with a clathrin-mediated uptake. Co-transport was also observed in breast cancer cells (35) . On the other hand, our data suggest that IGF-I inhibits IGFBP-3 internalization. These findings are not mutually exclusive but rather demonstrate that the uptake of these molecules is regulated in a complex inter-dependent fashion. Alternatively, IGF-inhibitable IGFBP-3 nuclear localization may be cell type-specific phenomena.
Caveolae are smooth flask-shaped invaginations of the plasma membrane that were first described in endothelial cells (36, 37) . They represent a subdomain of glycolipid rafts, cholesterol-and sphingolipid-rich membrane domains that are specifically associated with the cholesterol-binding caveolin proteins (38) . Caveolin-1, a 21-24-kDa integral membrane protein, is a major component of the caveolae membrane structures, with a flask-shaped invagination that is enriched with cholesterol and glycosphingolipid as well as with lipid-modified signaling proteins. Caveolin-1 has been implicated as a principal structural scaffold for the oligomerization and organization of cytoplasmic signal complexes (39) .
We have described recently (40) IGFBP-3 as an inhibitor of AKT phosphorylation. Another report details IGFBP-3 activation of intracellular phosphotyrosine phosphatases (41) . Our recognition of a caveolin-scaffolding domain consensus sequence (CSD, ØXØXXXXØ, where Ø is a hydrophobic residue and X is any amino acid residue) (12) , FCWCVDKY, near the C-terminal end of IGFBP-3 ( Fig. 1) , offered caveolin-1 as an attractive membrane protein partner for IGFBP-3 as well as a mediator of IGFBP-3 internalization. CSD sequences have been proposed to host and modulate a host of signaling molecules including H-Ras, Src family tyrosine kinases, protein kinase C isoforms, epidermal growth factor receptor, Neu, and endothelial nitric-oxide synthase. Caveolin-1 itself has been reported to associate with molecules such as the insulin receptor, TGF-␤ type I and II receptors, GLUT4, Stat3, COX-2, androgen receptor, and estrogen receptor (42) . Our data on the interaction between IGFBP-3 and caveolin suggest a functional interplay between the caveolin-scaffolding signal complex and IGFBP-3. Interaction between IGFBP-3 and this complex may function by providing an organizational mechanism for molecular interaction and maximizing signal transduction.
The observation that IGFBP-3 internalization occurs via two distinct pathways is not unique. GLUT4 uptake has been described via a non-caveolae-mediated process as well as peripheral association with large caveolin-containing domains (43) . In addition, the cellular uptake of influenza virus (44), interleukin-2 (45), cholera toxin (22) , Shiga toxin (46), epidermal growth factor receptor (47) , and insulin receptor (48) has been described to involve both internalization pathways.
Recent evidence uncovers a role for transduction of signals from clathrin-mediated endocytosis compartments. The observation that the activated epidermal growth factor receptor can be detected on endosomes where it can activate Ras indicates that it is the receptor itself that needs to be internalized to initiate signaling (49, 50) . Furthermore, nerve growth factormediated signaling illustrates how one molecule can mediate dichotomous functions; the activated Trk receptor induces survival when at the plasma membrane, whereas it elicits differentiation of neurite outgrowth if internalized (51) . Finally, the internalization of IGFBP-3-transferrin-TfR1 complex may possibly result in the eventual dissociation of IGFBP-3 from the transferrin-TfR1 complex in the acidic luminal endosomal compartment. This may liberate IGFBP-3 to interact with downstream effectors after sorting to endosomes that are permissive to signaling, whereas transferrin-TfR1 is targeted to lysosomes for degradation, similar to that described for Smo-ShhPtc complexes (52) .
We describe IGFBP-3 internalization via caveolin-and transferrin dependent pathways. Internalization, and subsequent IGFBP-3 function, may be determined by cell type differences in the relative action or abundance of the endocytic pathways discussed here. Future detailed microscopy work will be needed to determine which endocytic vesicles IGFBP-3 is trafficked through when it enters cells by clathrin-mediated (transferrin-dependent) and caveolae-mediated endocytosis. As yet, it is not clear why and how IGFBP-3 has the capacity to enter cells through multiple pathways. One obvious possibility is that IGFBP-3 binds proteoglycans (53) , heparin, and glycosaminoglycans (54) nonspecifically, which places it in proximity to forming endosomes of various pathways. Alternatively, distinct compartmental segregation during endocytosis might determine cytoplasmic signal transduction versus nuclear localization and differential effects on cellular growth and apo-ptosis, as recently reported (55) for the TGF-␤ receptor.
Taken together, our data indicate that IGFBP-3 enters cells by dual, distinct mechanisms: first, a caveolae-mediated endocytic pathway; and second, entry via a classical clathrin-mediated endocytic pathway via binding to transferrin-TfR1 complexes. Reminiscent of its role as a member of the 150-kDa serum ternary complex that mediates the endocrine actions of growth hormone, we have now described a cell surface ternary complex formation that is conducive to internalization.
It possible that other IGFBPs may have multiple entry pathways that could be dependent on receptor binding or cell type. After entry into cells, IGFBP-3 rapidly enters the nucleus within minutes, possibly through residue targeting or by its use of the nuclear localization sequence. Internalization and nuclear localization appear important for the apoptotic actions of IGFBP-3.
